Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617
Cancer · 15.04.2026 · 132 (8)
DOI: 10.1002/cncr.70410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 16.04.2026. Verfasst von Margo B Gerke und 17 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Institutes of Health/National Cancer Institute.
Abstract (Originalsprache)
Background
This study evaluates baseline inflammatory biomarkers prognostic of clinical outcomes for patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with Lutetium‐177 ( 177 Lu)–PSMA‐617.
Methods
A retrospective review of patients treated with 177 Lu–PSMA‐617 at Emory Winship Cancer Institute was conducted. Baseline inflammatory markers obtained included neutrophil‐to‐lymphocyte ratio (NLR), monocyte‐to‐lymphocyte ratio (MLR), platelet‐to‐lymphocyte ratio (PLR), systemic immune‐inflammation index (SII), pan‐immune‐inflammation value (PIV), and hemoglobin‐to‐platelet ratio (HPR). Cox proportional hazards models assessed overall survival (OS) and progression‐free survival (PFS), and a logistic regression model assessed ≥50% decline in prostate‐specific antigen (PSA) from baseline (PSA50). A prognostic biomarker composite score was generated using best‐subset variable selection from a multivariate Cox model.
Results
In this cohort of 163 patients (median age 73; 51.6% White, 43.6% Black) with mCRPC treated with 177 Lu–PSMA‐617, elevated NLR, PLR, PIV, SII, and reduced HPR were independent prognostic biomarkers of shortened OS (NLR hazard ratio [HR], 2.7, p = .002; PLR HR, 2.08, p = .015, PIV HR, 2.86, p = .002, SII HR, 2.5, p = .003; and HPR HR, 0.43, p = .011). Higher NLR, PLR, and SII values were independently prognostic of shortened PFS (NLR HR, 1.82, p = .012; PLR, 1.6, p = .036; and SII HR, 1.85, p = .009). Patients with elevated HPR and hemoglobin (Hgb) had higher odds of PSA50 response (HPR: 84.8% vs. 15.2%, p = .032, median Hgb of PSA50 response: 11.5 vs. 10.7, p = .01). The biomarker composite score stratified overall survival with good discrimination (C‐index = 0.732), demonstrating a reduction in mortality risk from the high‐tercile group to intermediate‐tercile (HR, 0.40, p = .022) and low‐tercile (HR, 0.16, p < .001).
Conclusions
Baseline inflammatory markers are associated with clinical outcomes for patients treated with 177 Lu–PSMA‐617.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emory University School of Medicine, Atlanta, Georgia, USA.
- Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
- Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA.
- Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University, Atlanta, Georgia, USA.
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Margo B Gerke, Angelo Marra, Akshay Bedmutha, Bassel Nazha, Jacob E Berchuck, Ravi Bharat Parikh, Mehmet Asim Bilen
Förderung
- National Institutes of Health/National Cancer Institute
Zitieren
APA
Gerke, M. B., Marra, A., Liu, Y., Bedmutha, A., Brown, J. T., Nazha, B., Berchuck, J. E., Parikh, R. B., Ahmed, S., Ciuro, J. A., Hartman, C., McClintock, G. R., Caulfield, S., Kucuk, O., Carthon, B. C., Schuster, D. M., Muzahir, S., & Bilen, M. A. (2026). Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617. Cancer, 132(8). https://doi.org/10.1002/cncr.70410
Vancouver
Gerke MB, Marra A, Liu Y, Bedmutha A, Brown JT, Nazha B, et al. Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617. Cancer. 2026;132(8). doi:10.1002/cncr.70410
BibTeX
@article{Gerke2026,
author = {Gerke, Margo B and Marra, Angelo and Liu, Yuan and Bedmutha, Akshay and Brown, Jacqueline T and Nazha, Bassel and Berchuck, Jacob E and Parikh, Ravi Bharat and Ahmed, Shahid and Ciuro, Jordan Alana and Hartman, Caitlin and McClintock, Greta Russler and Caulfield, Sarah and Kucuk, Omer and Carthon, Bradley Curtis and Schuster, David M and Muzahir, Saima and Bilen, Mehmet Asim},
title = {Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617},
journal = {Cancer},
year = {2026},
volume = {132},
number = {8},
doi = {10.1002/cncr.70410}
}
EUVIMED